Akoya Biosciences (AKYA) to Release Earnings on Monday

Akoya Biosciences (NASDAQ:AKYA) is expected to be announcing its Q1 2025 earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $20.19 million for the quarter.

Akoya Biosciences (NASDAQ:AKYA) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Akoya Biosciences had a negative return on equity of 162.99% and a negative net margin of 66.77%. The firm had revenue of $21.34 million for the quarter, compared to analyst estimates of $21.34 million. On average, analysts expect Akoya Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Akoya Biosciences Trading Down 1.8 %

Shares of NASDAQ:AKYA opened at $1.12 on Friday. The company has a market cap of $55.86 million, a PE ratio of -0.95 and a beta of 1.34. The company’s 50 day moving average is $1.33 and its two-hundred day moving average is $2.10. Akoya Biosciences has a 52 week low of $1.01 and a 52 week high of $4.42. The company has a current ratio of 2.75, a quick ratio of 1.85 and a debt-to-equity ratio of 5.62.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Piper Sandler cut their price target on Akoya Biosciences from $2.40 to $1.65 and set a “neutral” rating on the stock in a research note on Monday, April 14th. Canaccord Genuity Group decreased their target price on Akoya Biosciences from $3.50 to $1.80 and set a “hold” rating for the company in a research note on Tuesday, April 29th. Finally, Stephens reiterated an “equal weight” rating and issued a $1.80 price target (down from $3.50) on shares of Akoya Biosciences in a research note on Tuesday, March 25th. Seven investment analysts have rated the stock with a hold rating, According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $3.21.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Akoya Biosciences stock. Bank of America Corp DE grew its position in Akoya Biosciences, Inc. (NASDAQ:AKYA) by 39.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 29,092 shares of the company’s stock after acquiring an additional 8,258 shares during the quarter. Bank of America Corp DE owned about 0.06% of Akoya Biosciences worth $67,000 at the end of the most recent reporting period. 79.42% of the stock is owned by institutional investors.

About Akoya Biosciences

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.